Effective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1

PURPOSE: In medulloblastoma (MB), group 3 (G3) patients with MYC amplification tend to exhibit worse prognosis, thus creating a need for novel effective therapies. As the driver and crucial dependency for MYC-amplified G3-MB, MYC has been proven to be a prospective therapeutic target. Here, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yang, Li, Tiantian, Tian, Shuaiwei, Meng, Wei, Sui, Yi, Yang, Jian, Wang, Baocheng, Liang, Zhuangzhuang, Zhao, Heng, Han, Yipeng, Tang, Yujie, Zhang, Lei, Ma, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721120/
https://www.ncbi.nlm.nih.gov/pubmed/33299354
http://dx.doi.org/10.2147/CMAR.S278844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721120/
https://www.ncbi.nlm.nih.gov/pubmed/33299354
http://dx.doi.org/10.2147/CMAR.S278844

Ejemplares similares